IMARC Group has recently released a report titled “Ankylosing Spondylitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the ankylosing spondylitis market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Ankylosing spondylitis (AS) refers to a chronic inflammatory disease that mainly affects the joints of the spine, which leads to stiffness and pain. The symptoms of this condition begin in the sacroiliac joints and can gradually lead to the fusion of the spinal bones, which further results in the loss of mobility and flexibility in the spine. Moreover, AS is classified as a type of inflammatory arthritis that can persist throughout a person’s lifetime. The diagnosis of AS can be confirmed if an X-ray shows swelling on the sacroiliac joints, and the individual must have at least 1 of the following conditions: a minimum of three months of continuous lower back pain, limited chest expansion, or limited movement in the lower back.
Request a Free Sample Report: https://www.imarcgroup.com/ankylosing-spondylitis-market/requestsample
Market Trend:
The growing prevalence of inflammatory arthritis along with the escalating demand for effective medications to treat this condition is primarily driving the ankylosing spondylitis market. Besides this, the increasing awareness regarding the importance of early diagnosis and treatment of AS is also catalyzing the market growth. Additionally, the inflating adoption of biologic medications, which are more effective in treating ankylosing spondylitis than conventional non-biologic drugs, is creating a positive outlook for the market. In line with this, the growing popularity of disease-modifying anti-rheumatic drugs (DMARDs), as they help slow the disease progression, is also augmenting the market growth. Moreover, the rising preferences for physical rehabilitation and therapies to maintain mobility and prevent spinal fusion are anticipated to propel the growth of the ankylosing spondylitis market in the coming years.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the ankylosing spondylitis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the ankylosing spondylitis market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/ankylosing-spondylitis-market
Key Questions Answered in this Report:
- How has the ankylosing spondylitis market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the ankylosing spondylitis market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the ankylosing spondylitis market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Ankylosing Spondylitis – Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Ankylosing Spondylitis – Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Ankylosing Spondylitis – Epidemiology and Patient Population
7.1 Epidemiology – Key Insights
7.2 Epidemiology Scenario – Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.2.3 Epidemiology by Age (2017-2033)
7.2.4 Epidemiology by Gender (2017-2033)
7.2.5 Epidemiology by Type (2017-2033)
7.2.6 Diagnosed Cases (2017-2033)
7.2.7 Patient Pool/Treated Cases (2017-2033)
7.3 Epidemiology Scenario – United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.3.3 Epidemiology by Age (2017-2033)
7.3.4 Epidemiology by Gender (2017-2033)
7.3.5 Epidemiology by Type (2017-2033)
7.3.6 Diagnosed Cases (2017-2033)
7.3.7 Patient Pool/Treated Cases (2017-2033)
7.4 Epidemiology Scenario – Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.4.3 Epidemiology by Age (2017-2033)
7.4.4 Epidemiology by Gender (2017-2033)
7.4.5 Epidemiology by Type (2017-2033)
7.4.6 Diagnosed Cases (2017-2033)
7.4.7 Patient Pool/Treated Cases (2017-2033)
7.5 Epidemiology Scenario – France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.5.3 Epidemiology by Age (2017-2033)
7.5.4 Epidemiology by Gender (2017-2033)
7.5.5 Epidemiology by Type (2017-2033)
7.5.6 Diagnosed Cases (2017-2033)
7.5.7 Patient Pool/Treated Cases (2017-2033)
7.6 Epidemiology Scenario – United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.6.3 Epidemiology by Age (2017-2033)
7.6.4 Epidemiology by Gender (2017-2033)
7.6.5 Epidemiology by Type (2017-2033)
7.6.6 Diagnosed Cases (2017-2033)
7.6.7 Patient Pool/Treated Cases (2017-2033)
7.7 Epidemiology Scenario – Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.7.3 Epidemiology by Age (2017-2033)
7.7.4 Epidemiology by Gender (2017-2033)
7.7.5 Epidemiology by Type (2017-2033)
7.7.6 Diagnosed Cases (2017-2033)
7.7.7 Patient Pool/Treated Cases (2017-2033)
7.8 Epidemiology Scenario – Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.8.3 Epidemiology by Age (2017-2033)
7.8.4 Epidemiology by Gender (2017-2033)
7.8.5 Epidemiology by Type (2017-2033)
7.8.6 Diagnosed Cases (2017-2033)
7.8.7 Patient Pool/Treated Cases (2017-2033)
7.9 Epidemiology Scenario – Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)
7.9.3 Epidemiology by Age (2017-2033)
7.9.4 Epidemiology by Gender (2017-2033)
7.9.5 Epidemiology by Type (2017-2033)
7.9.6 Diagnosed Cases (2017-2033)
7.9.7 Patient Pool/Treated Cases (2017-2033)
8 Ankylosing Spondylitis – Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Ankylosing Spondylitis – Unmet Needs
10 Ankylosing Spondylitis – Key Endpoints of Treatment
11 Ankylosing Spondylitis – Marketed Products
11.1 List of Ankylosing Spondylitis Marketed Drugs Across the Top 7 Markets
11.1.1 RINVOQ- AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 XELJANZ – Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 TALTZ – Eli Lilly
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 SIMPONI – Janssen Biotech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Remicade (infliximab) – Janssen Biotech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
12 Ankylosing Spondylitis – Pipeline Drugs
12.1 List of Ankylosing Spondylitis Pipeline Drugs Across the Top 7 Markets
12.1.1 AK111 – Akeso
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Secukinumab – Novartis Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Bimekizumab – UCB Biopharma SRL
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CC-99677 – Celgene
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report
13. Ankylosing Spondylitis – Attribute Analysis of Key Marketed and Pipeline Drugs
14. Ankylosing Spondylitis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Ankylosing Spondylitis – Market Scenario
15.1 Market Scenario – Key Insights
15.2 Market Scenario – Top 7 Markets
15.2.1 Ankylosing Spondylitis – Market Size
15.2.1.1 Market Size (2017-2022)
15.2.1.2 Market Forecast (2023-2033)
15.2.2 Ankylosing Spondylitis – Market Size by Therapies
15.2.2.1 Market Size by Therapies (2017-2022)
15.2.2.2 Market Forecast by Therapies (2023-2033)
15.3 Market Scenario – United States
15.3.1 Ankylosing Spondylitis – Market Size
15.3.1.1 Market Size (2017-2022)
15.3.1.2 Market Forecast (2023-2033)
15.3.2 Ankylosing Spondylitis – Market Size by Therapies
15.3.2.1 Market Size by Therapies (2017-2022)
15.3.2.2 Market Forecast by Therapies (2023-2033)
15.3.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.4 Market Scenario – Germany
15.4.1 Ankylosing Spondylitis – Market Size
15.4.1.1 Market Size (2017-2022)
15.4.1.2 Market Forecast (2023-2033)
15.4.2 Ankylosing Spondylitis – Market Size by Therapies
15.4.2.1 Market Size by Therapies (2017-2022)
15.4.2.2 Market Forecast by Therapies (2023-2033)
15.4.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.5 Market Scenario – France
15.5.1 Ankylosing Spondylitis – Market Size
15.5.1.1 Market Size (2017-2022)
15.5.1.2 Market Forecast (2023-2033)
15.5.2 Ankylosing Spondylitis – Market Size by Therapies
15.5.2.1 Market Size by Therapies (2017-2022)
15.5.2.2 Market Forecast by Therapies (2023-2033)
15.5.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Ankylosing Spondylitis – Market Size
15.6.1.1 Market Size (2017-2022)
15.6.1.2 Market Forecast (2023-2033)
15.6.2 Ankylosing Spondylitis – Market Size by Therapies
15.6.2.1 Market Size by Therapies (2017-2022)
15.6.2.2 Market Forecast by Therapies (2023-2033)
15.6.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Ankylosing Spondylitis – Market Size
15.7.1.1 Market Size (2017-2022)
15.7.1.2 Market Forecast (2023-2033)
15.7.2 Ankylosing Spondylitis – Market Size by Therapies
15.7.2.1 Market Size by Therapies (2017-2022)
15.7.2.2 Market Forecast by Therapies (2023-2033)
15.7.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.8 Market Scenario – Spain
15.8.1 Ankylosing Spondylitis – Market Size
15.8.1.1 Market Size (2017-2022)
15.8.1.2 Market Forecast (2023-2033)
15.8.2 Ankylosing Spondylitis – Market Size by Therapies
15.8.2.1 Market Size by Therapies (2017-2022)
15.8.2.2 Market Forecast by Therapies (2023-2033)
15.8.3 Ankylosing Spondylitis – Access and Reimbursement Overview
15.9 Market Scenario – Japan
15.9.1 Ankylosing Spondylitis – Market Size
15.9.1.1 Market Size (2017-2022)
15.9.1.2 Market Forecast (2023-2033)
15.9.2 Ankylosing Spondylitis – Market Size by Therapies
15.9.2.1 Market Size by Therapies (2017-2022)
15.9.2.2 Market Forecast by Therapies (2023-2033)
15.9.3 Ankylosing Spondylitis – Access and Reimbursement Overview
16 Ankylosing Spondylitis – Recent Events and Inputs From Key Opinion Leaders
17 Ankylosing Spondylitis Market – SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Ankylosing Spondylitis – Strategic Recommendations
19 Appendix